Clinical Investigation Centre, Inserm 1413, University Hospital, Nantes, France.
Department of Pediatrics and Pediatric Emergency, University Hospital, Nantes, France.
Clin Chem Lab Med. 2020 Nov 25;59(5):875-882. doi: 10.1515/cclm-2020-1293. Print 2021 Apr 27.
To evaluate the impact of implementing a modified Pediatric Emergency Care Applied Research Network (PECARN) rule including the S100B protein assay for managing mild traumatic brain injury (mTBI) in children.
A before-and-after study was conducted in a paediatric emergency department of a French University Hospital from 2013 to 2015. We retrospectively included all consecutive children aged 4 months to 15 years who presented mTBI and were at intermediate risk for clinically important traumatic brain injury (ciTBI). We compared the proportions of CT scans performed and of in-hospital observations before (2013-2014) and after (2014-2015) implementation of a modified PECARN rule including the S100B protein assay.
We included 1,062 children with mTBI (median age 4.5 years, sex ratio [F/M] 0.73) who were at intermediate risk for ciTBI: 494 (46.5%) during 2013-2014 and 568 (53.5%) during 2014-2015. During 2014-2015, S100B protein was measured in 451 (79.4%) children within 6 h after mTBI. The proportion of CT scans and in-hospital observations significantly decreased between the two periods, from 14.4 to 9.5% (p=0.02) and 73.9-40.5% (p<0.01), respectively. The number of CT scans performed to identify a single ciTBI was reduced by two-thirds, from 18 to 6 CT scans, between 2013-2014 and 2014-2015. All children with ciTBI were identified by the rules.
The implementation of a modified PECARN rule including the S100B protein assay significantly decreased the proportion of CT scans and in-hospital observations for children with mTBI who were at intermediate risk for ciTBI.
评估实施改良儿科急诊护理应用研究网络(PECARN)规则,包括 S100B 蛋白检测,对管理儿童轻度创伤性脑损伤(mTBI)的影响。
本研究是一项在法国大学医院儿科急诊部门进行的前后对照研究,时间为 2013 年至 2015 年。我们回顾性纳入所有连续就诊的年龄在 4 个月至 15 岁之间、mTBI 且存在中等程度临床相关创伤性脑损伤(ciTBI)风险的患儿。我们比较了改良 PECARN 规则(包括 S100B 蛋白检测)实施前后(2013-2014 年和 2014-2015 年)CT 扫描和住院观察的比例。
共纳入 1062 例 mTBI 患儿(中位年龄 4.5 岁,男女比例 0.73),其中 494 例(46.5%)在 2013-2014 年,568 例(53.5%)在 2014-2015 年。在 2014-2015 年,有 451 例(79.4%)患儿在 mTBI 后 6 小时内进行了 S100B 蛋白检测。两个时期 CT 扫描和住院观察的比例显著下降,分别从 14.4%降至 9.5%(p=0.02)和从 73.9%降至 40.5%(p<0.01)。为识别单个 ciTBI 进行的 CT 扫描数量减少了三分之二,从 2013-2014 年的 18 次降至 2014-2015 年的 6 次。所有 ciTBI 患儿均被规则识别。
实施改良 PECARN 规则,包括 S100B 蛋白检测,显著降低了中等程度 ciTBI 风险 mTBI 患儿的 CT 扫描和住院观察比例。